non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: Daily intake of total anthocyanin base standardized (cornus mas L.) fruit extract (equal to 320 mg/d anthocyanins) for 12 weeks. Intervention 2: Control group: Dail
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
25 Years to 65 Years
Inclusion criteria
Inclusion criteria: ALT levels more than 30 U / L in men and more than 19 U / L in women Age 25-26 years Diagnosis of the disease by ultrasonography and by a gastroenterologist The patients with grade 1, 2 and 3 fatty liver The consent of subject to participate in the study The patients are from Yazd
Exclusion criteria
Exclusion criteria: The history of diseases including cirrhosis, viral hepatitis, cardiovascular disease, diabetes, Wilson and cancer. Consumption of medications including corticosteroids, nonsteroidal anti-inflammatory drugs, hypoglycemic agents or any medicine that affect blood glucose, tamoxifen, sodium valproate, methotrexate, probiotics, any medicine or supplement that affect liver function, supplements with antioxidant and anti-inflammatory properties (such as vitamin D, vitamin E, omega-3, resveratrol) during 1 month before the study Following a special diet during 1 month before the study Pregnancy and breastfeeding ?lcohol consumption
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum levels of Alanine Aminotransferase (ALT). Timepoint: Before and after the 12-week intervention. Method of measurement: By autoanalyzer.;Serum levels of Aspartate Aminotransaminase (AST). Timepoint: Before and after the 12-week intervention. Method of measurement: By autoanalyzer.;Serum levels of Tumor necrosis factor a (TNF-a). Timepoint: Before and after the 12-week intervention. Method of measurement: By ELISA kit.;Serum levels of Malondealdehyde (MDA). Timepoint: Before and after the 12-week intervention. Method of measurement: By ELISA kit.;Serum levels of adiponectin. Timepoint: Before and after the 12-week intervention. Method of measurement: By ELISA kit.;Serum levels of cytokeratin-18 fragment M30 (CK-18 M30). Timepoint: Before and after the 12-week intervention. Method of measurement: By ELISA kit.;Liver steatosis. Timepoint: Before and after the 12-week intervention. Method of measurement: By ultrasonography.;Liver fibrosis. Timepoint: Before and after the 12-week intervention. Method of measurement: By fibroscan. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting blood glucose (FBS). Timepoint: Before and after the 12-week intervention. Method of measurement: By autoanalyzer.;Serum levels of Triglyceride (TG). Timepoint: Before and after the 12-week intervention. Method of measurement: By autoanalyzer.;Serum levels of High-density lipoprotein (HDL). Timepoint: Before and after the 12-week intervention. Method of measurement: By autoanalyzer.;Serum levels of Low-density lipoprotein (LDL). Timepoint: Before and after the 12-week intervention. Method of measurement: By autoanalyzer.;Serum levels of total cholesterol. Timepoint: Before and after the 12-week intervention. Method of measurement: By autoanalyzer.;Serum levels of insulin. Timepoint: Before and after the 12-week intervention. Method of measurement: By ELISA kit.;Insulin resistance. Timepoint: Before and after the 12-week intervention. Method of measurement: By HOMA-IR and QUICKI.;Lipid accumulation product. Timepoint: Before and after the 12-week intervention. Method of measurement: Formula.;Atherogenic index of plasma. Timepoint: Before and after the 12-week intervention. Method of measurement: Formula.;Atherogenic coefficient. Timepoint: Before and after the 12-week intervention. Method of measurement: Formula.;Castelli 1 index. Timepoint: Before and after the 12-week intervention. Method of measurement: Formula.;Castelli 2 index. Timepoint: Before and after the 12-week intervention. Method of measurement: Formula.;TyG index. Timepoint: Before and after the 12-week intervention. Method of measurement: Formula.;Fatty liver index. Timepoint: Before and after the 12-week intervention. Method of measurement: Formula.;Hepatic steatosis index. Timepoint: Before and after the 12-week intervention. Method of measurement: Formula.;Visceral adiposity index. Timepoint: Before and after the 12-week intervention. Method of measurement: Formula.;NAFLD-liver fat score. Timepoint: Before and after the 12-week intervention. Method of measurement: Formula.;Estimated glucose | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZohreh Sadat Sangsefidi
Yazd University of Medical Sciences
Outcome results
None listed